COM_RESEARCHSTUDIES_DETAIL_AVAL_STATUS_4

Autologous Anti-HER2 Chimeric Antigen Receptor Monocytes (CT-0525) in Participants with HER2 Over Expressing Solid Tumors

The purpose of this study is to learn about the effects of a research investigational product, CT-0525, and to see if CT-0525 is safe for participants with advanced cancer. This study is the first time that CT-0525 will be given to humans. CT-0525 is a special kind of product that is made of blood cells taken from your own body. Once collected, these blood cells will be altered and infused back into your body.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4

United States (Nationwide)

Additional Study Information

Principal Investigator

Yara Abdou
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Phase 1 Trials (all cancers))

IRB Number

23-1931

ClinicalTrials.gov

NCT06254807

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.